Jason Rubin, president and founder of The Redstone Group, LLC, has more than thirty years of communications and management consulting experience advising biotechnology, pharmaceutical and technology companies on a wide range of public and investor relations issues.

As director of the biotechnology group at Hill and Knowlton, Jason managed one of the world’s largest and most successful public and investor relations consulting practices for pharmaceutical and emerging biotechnology companies.

He has served as vice president and senior communications officer for four biotechnology companies (Immunex, Cephalon, Centocor and Incyte), where he was responsible for managing communications involving some of the industry’s most visible and challenging product stories. A passion for healthcare and an understanding of the financial community are reflected in his reputation for integrity, creativity and accuracy among reporters, analysts, investors and industry leaders.

Jason has also participated in numerous corporate road shows and merger and acquisition transactions, including the acquisition of Immunex by American Cyanamid, the $5 billion merger between Centocor and Johnson & Johnson and the 2004 acquisition of Esperion by Pfizer – singular experience which has given him a useful perspective on the strategic shifts and challenges facing pharmaceutical and biotechnology companies today.

He has served as chair of the Biotechnology Industry Organization communications committee and for eight years as a director of the Pennsylvania Biotechnology Association. For three years he was commissioning editor of Biotechnology Investors' Forum, published by Euromoney Institutional Investor. He has been a frequent speaker on investor relations at numerous industry conferences.

Jason is a graduate of Middlebury College and the Sloan School of Management at MIT.